TrialJournal of cancer research and clinical oncology2023

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.

Qing Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.